Interim HCV genotype 3 data from BIT225-008 study
Filed with ASX · · 3 pages · English
Earlier from Biotron
Later from Biotron
- Biotron compounds tested for activity against Zika virus
- BIT225 May have a broader role in limiting HIV-1 infection
- Phase 2 Hepatitis C Trial Success
- Trading halt
- $1.5 Million R&D Tax Rebate
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron